Newer Retina Treatments Show Slightly Higher Inflammation Rates

Aflibercept and Faricimab Raise Concerns About Increased Intraocular Inflammation

Mar. 12, 2026 at 11:53am

Got story updates? Submit your updates here. ›

The field of retinal disease treatment is evolving rapidly, with new therapies like high-dose aflibercept (Eylea HD) and faricimab (Vabysmo) emerging as potential alternatives to established protocols. However, recent discussions at the Retina 2026 conference have highlighted a potential increase in intraocular inflammation (IOI) associated with these newer treatments, requiring heightened vigilance and continued data collection.

Why it matters

The potential for increased inflammation with Eylea HD and Vabysmo underscores the importance of robust postmarketing surveillance to fully understand the benefits and risks of these newer agents. Careful monitoring of patients receiving these treatments will be crucial to ensure their safety and efficacy.

The details

According to Michael S. Ip, MD, of Doheny Eye Center UCLA Arcadia, both Eylea HD and Vabysmo have shown 'slightly higher' IOI events compared to previous treatments. While the clinical significance of this observation is still being determined, it highlights the need for continued research and data collection to refine treatment protocols and personalize care for patients.

  • The Retina 2026 conference recently discussed the potential increase in intraocular inflammation associated with newer retinal treatments.

The players

Michael S. Ip, MD

A physician at Doheny Eye Center UCLA Arcadia who noted the slightly higher intraocular inflammation rates associated with Eylea HD and Vabysmo.

Eylea HD

A high-dose version of the anti-VEGF medication aflibercept, which is used to treat retinal diseases.

Vabysmo

A newer anti-VEGF medication called faricimab, which is also used to treat retinal diseases.

Got photos? Submit your photos here. ›

What they’re saying

“Slightly higher' IOI events associated with both Eylea HD and Vabysmo.”

— Michael S. Ip, MD, Physician, Doheny Eye Center UCLA Arcadia

What’s next

The SPECTRUM study, investigating aflibercept 8 mg for diabetic macular edema and neovascular age-related macular degeneration, is eagerly anticipated. Real-world data from studies like SPECTRUM will be crucial in providing a more comprehensive understanding of the benefits and risks associated with these newer agents.

The takeaway

The focus on intraocular inflammation is part of a larger trend toward optimizing treatment efficacy while minimizing side effects in retinal care. Continued research, robust postmarketing surveillance, and the use of emerging technologies like AI will be key to refining treatment protocols and ensuring the safety and efficacy of newer retinal therapies.